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Abstract 
We present hot melt extrusion (HME) for the design of floating multiparticulates. Metoprolol 
succinate was selected as the model drug. Our foremost objective was to optimize the 
components Eudragit® RS PO, polyethylene oxide (PEO) and hydroxypropyl methylcellulose 
(HPMC) to balance both buoyancy and controlled release. Gas generated by sodium 
bicarbonate in acidic medium was trapped in the polymer matrix to enable floating. Eudragit® 
RS PO and PEO with sodium bicarbonate resulted in multiparticulates which exhibited rapid 
flotation within 3 minutes but inadequate total floating time (TFT) of 3 hours. Addition of 
HPMC to the matrix did not affect floating lag time (FLT), moreover TFT increased to more 
than 12 hours with controlled release of metoprolol succinate. Floating multiparticulates 
exhibited t50% of 5.24 hours and t90% of 10.12 hours. XRD and DSC analysis revealed 
crystalline state of drug while FTIR suggested nonexistence of chemical interaction between 
the drug and the other excipients. The assay, FLT, TFT and the drug release of the 
multiparticulates were unchanged when stored at 40°C/75%RH for 3 months confirming 
stability. We present floating multiparticulates by HME which could be extrapolated to a 
range of other drugs. Our approach hence presents platform technology for floating 
multiparticulates. 
Key words 
Hot melt extrusion, Floating multiparticulates, Sodium bicarbonate, Metoprolol succinate, 
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Chemical compounds studied in this article 
Metoprolol succinate (PubChem CID: 4171); Sodium bicarbonate (PubChem CID: 516892); 
Glyceryl monostearate (PubChem CID: 24699); Hydrochloric acid (PubChem CID: 313) 
1. Introduction 
Gastric residence time is an important factor affecting drug absorption and bioavailability 
(Desai and Bolton, 1993). Prolonging the gastric residence time of drug delivery systems is 
positively considered for design of controlled release formulations (Sauzet et al., 2009) of 
drugs having absorption window in the upper GIT and drugs exhibiting poor solubility in the 
basic pH of the intestinal milieu (Klausner et al., 2003, Singh and Kim, 2000; Jain et al., 
2005). Floating systems provide a simple and sensible approach of gastroretention without 
adversely affecting the motility of the GIT (Tang et al., 2007). Monolithic (Qi et al., 2015) 
including layered tablets (Desai et al., 2014,) and multiparticulate floating systems may be 
designed, nevertheless multiparticulates provide specific advantages for controlled drug 
delivery. 
Ion exchange resins coated with a semipermeable membrane exhibited prolonged gastric 
retention and controlled release of theophylline (Atyabi et al., 1996). Drug loaded pellets of 
p-aminobenzoic acid (Ichigawa et al., 1991), zolpidem tartarate (Amrutkar et al., 2012) and 
theophylline (Sungthongjeen et al., 2006) coated with an inner effervescent layer and outer 
polymeric layer enabled prolonged floating with controlled drug release. Coated beads of 
calcium alginate prepared by ionotropic gelation exhibited immediate buoyancy and 
remained floating for prolonged periods (Iannuccelli et al., 1998). Floating microspheres of 
ranitidine hydrochloride (Saravanan and Anupama., 2011) verapamil hydrochloride (Streubel 
et al., 2002) and itopride hydrochloride (Bansal et al., 2014) were developed by solvent 
evaporation method, while the emulsion solvent diffusion method was effectively employed 
for preparation of floating microballoons which exhibited controlled release of riboflavin 
(Sato et al., 2003, 2004, Upadhyay et al., 2013), tranilast (Kawashima et al., 1992) and 
psoralen (Liu et al., 2011). Drug loaded porous calcium silicate microspheres coated with 
Eudragit® S also exhibited floating and controlled release (Jain et al., 2005). Multi-step 
processing and the need for organic solvents is a common feature of the above methods 
(Hamdani et al., 2006). 
Hot melt extrusion (HME) is a recent versatile, green and scalable technology (Repka et al., 
2007, Mooter 2012) amenable for continuous manufacturing and also process analytical 
technology (PAT) enabled (Islam et al., 2014). Matrix mini tablets of ibuprofen (De 
Brabander et al., 2003), lipid matrices of diclofenac sodium (Vithani et al., 2013) and 
extrudates of phenylpropanolamine hydrochloride (Sarraf et al., 2015) prepared by HME 
exhibited sustained release. In general HME may be considered a densification technique. 
Sustained release of paracetamol from pellets processed by HME was attributed to 
densification of the pellets (Roblegg et al., 2011). Nevertheless a floating dosage form of 
nicardipine hydrochloride was successfully developed by HME using a twin-screw extruder 
with puff ability (Nakamichi et al., 2001).  Fukuda et al. (2006) reported porous floating 
tablets (6 mm diameter) of chlorpheniramine maleate by generating effervescence during the 
HME process and trapping the released gas in the   extrudates wherein extrudates were cut to 
obtain porous tablets. We present in this paper extruded floating multiparticulates by a 
standard HME process wherein in situ gas generation enabled buoyancy. Metoprolol 
succinate was selected as model drug for the feasibility study. The aim of the study was to 
exploit HME as a green and scalable process for the design of floating multiparticulates of 
metoprolol succinate. The specific objective of the study was to optimize the components of 
the floating multiparticulate system to balance both buoyancy and controlled release. 
 
2. Materials and methods 
2.1. Materials 
Metoprolol succinate was kindly gifted by Phoenix Pharmaceuticals LLC, USA. Sodium 
bicarbonate was obtained from s. d. fine chemicals, Mumbai. Hydroxypropyl methylcellulose 
(HPMC; Methocel K100M) was supplied by Colorcon Asia Pvt. Ltd. Eudragit® RS PO was 
gifted by Evonik Degussa, Mumbai,  glyceryl monostearate by Gattefosse India Pvt. Ltd. and 
polyethylene oxide (PEO; POLYOX™ WSR-303) by Colorcon Asia Pvt Ltd. 
 
2.2. Preparation of floating multiparticulates 
A mixture of metoprolol succinate, sodium bicarbonate, glyceryl monostearate and the 
polymers was sifted through sieve no. 40 and hand blended in a polyethylene bag for 15 min. 
The mixture was extruded on a HME (Thermo Scientific™ Pharma 11 twin-screw extruder) 
using a die of 2mm diameter. The hopper screw speed was set at 4 rpm. The screw rotation 
speed was set at 15 rpm to obtain a residence time of approximately 9 min. The temperature 
settings of the extruder zones were as follows: zone 2 (40°C), zone 3 (100°C), zone 4 
(100°C), zone 5 (120°C), zone 6 (120°C), zone 7 (125°C), zone 8 (125°C) and die (128°C). 
The torque limit was set at 90 Nm. The extrudates were allowed to attain room temperature 
(28°C) and cut in to segments of 5 mm length using a cutting blade. The polymers evaluated 
were PEO from 30 to 65% (w/w), Eudragit® RS PO from 10 to 75% (w/w) and HPMC from 
10 to 20% (w/w) in combination.  Sodium bicarbonate selected as effervescent agent was 
varied from 5 to 15% (w/w). The concentration of the drug metoprolol succinate and glyceryl 
monostearate which was included as a thermal lubricant was maintained constant at 10% 
(w/w) and 5% (w/w) respectively. 
 
2.3. Evaluation of floating multiparticulates 
2.3.1. Drug content 
Extrudates were crushed using a mortar and pestle, and an amount equivalent to 50 mg of 
metoprolol succinate was accurately weighed and transferred to a 200 mL volumetric flask 
and distilled water was added. The flask was sonicated in a bath sonicator for 1 h with 
intermittent shaking, the volume made up with distilled water and an aliquot (10mL) 
centrifuged at 5000 rpm for 5 min. The supernatant (2mL) was diluted to 10mL with distilled 
water and analysed spectrophotometrically (UV1650PC, Schimadzu Corporation USA) at λ 
max of 274nm. 
 
2.3.2. In-vitro buoyancy studies 
In-vitro buoyancy was assessed by monitoring two parameters, namely floating lag time 
(FLT) and total floating time (TFT) in 900 mL of 0.1N HCl maintained at 37°C,  using USP 
type II dissolution apparatus (Electrolab TDT- 08L) at a  paddle speed of 50 rpm. The 
extrudates were dropped in to the medium and the FLT was calculated as the time taken for 
100% extrudates to exhibit floating.  The TFT was the time at which a single extrudate sank 
in the medium. 
 
2.3.3. In-vitro drug release study 
Extrudates equivalent to 50 mg metoprolol succinate were filled in off white coloured hard 
gelatin capsules of size 00. Dissolution (n=6) was performed in 500mL of 0.1N HCl 
maintained at 37°C using USP type II dissolution apparatus (Electrolab TDT- 08L) at a 
paddle speed at 50 rpm. At predetermined time intervals, 5mL sample was withdrawn and 
replaced with fresh medium (37°C). Samples were analysed spectrophotometrically 
(UV1650PC, Schimadzu Corporation USA) at λ max of 274nm. The similarity factor (f2) and 
difference factor (f1) implemented by the U.S. FDA was employed to compare dissolution 
profiles between the formulations (U.S. FDA, 1997, Pillay and Fassihi, 1998, Shah et al., 
1998). The f2 is a logarithmic transformation of the sum squared error of differences between 
the test and reference product, and was calculated using equation 1. 
       (1) 
where Rt is cumulative release rate of the reference product, Tt is cumulative release rates of 
test product at the predetermined time period and n is the number of the time points. The f2 
value ≥ 50 indicates similarity between two dissolution profiles. The f1 value is the function 
of the average absolute difference between the two dissolution profiles and was calculated by 
the equation 2. 
         (2) 
where Rt and Tt are the cumulative release rates of the reference and test product at the 
determined time period respectively, and n is the number of the time points. The f1 calculates 
the percent difference between the two dissolution profiles at each time point and is a 
measurement of the relative error between the two curves. The f1 values up to 15 ensure 
sameness or equivalence of the test (post change) and reference (prechange) products. 
 
2.3.4. Drug release kinetics 
The in-vitro drug release data of the optimized formulation was subjected to different 
mathematical models, i.e. zero order, first order, Hixson–Crowell model, Higuchi, and 
Korsmeyer–Peppas models (Higuchi, 1963, Korsmeyer et al., 1983, Costa and Sousa Lobo, 
2001) as follows. 
Zero-order model: Q = kt + Q0 
Where Q is the amount of drug released in time t, Q0 indicates the initial drug amount 
(generally Q0 = 0) and k represents the rate constant. 
First-order model: Q = Q0ekt 
Where Q is the amount of drug released in time t, Q0 indicates the initial drug amount and k 
represents the rate constant. 
Hixson–Crowell model: Q1/3 = kt + Q01/3  
Where Q is the amount of drug released in time t, Q0 indicates the initial drug amount and k 
represents the rate constant. 
Higuchi model: Q = kt1/2 
Where Q is the amount of drug released in time t, and k represents the rate constant. 
Korsmeyer–Peppas model: Q = ktn 
where Q is the amount of drug released in time t, k represents the rate constant and  n is the 
diffusion exponent which indicates the mechanism of drug release. 
 
2.3.5. Length, diameter and density evaluation 
The length and diameter of extrudates was measured with the help of a vernier calliper. The 
density (D) of extrudates was calculated from weight, length and diameter of extrudates using 
the following equation commonly used for density measurements of cylinders. 
          (3) 
Where w is the weight, d is the diameter, π is the circular constant and h is the length of the 
extrudate. All measurements were performed in six replicates and the averages and standard 
deviations were calculated. 
 
2.3.6. X-ray diffraction (XRD) analysis 
XRD analysis was carried out on a Panalytical Xpert PRO MPD diffractometer equiped with 
xcelerator with diffracted beam monochromator detector, variable slits and a 0.050 step size, 
operated at a voltage of 45KV and 40mA current, 2θ/min scanning speed and wavelength of 
1.5405 Angstorm. 
 
2.3.7. Differential scanning calorimetry (DSC) analysis 
DSC analysis was carried out using Perkin Elmer, Pyris 6 DSC (Perkin Elmer life & 
Analytical Sciences Inc., USA) system in the temperature range 30 -300°C at a heating rate 
of 10°C /min in a dynamic nitrogen atmosphere (17 ml/min). Approximately 5 mg of sample 
was sealed in an aluminium DSC pan and an empty sealed aluminium pan was used as the 
reference. 
 
2.3.8. Fourier transform infrared (FTIR) analysis 
FTIR spectra were determined on a Shimadzu MIRACLE IR Affinity-1 FTIR 
spectrophotometer. The samples were premixed with KBr using a mortar and pestle and discs 
were prepared by means of a hydraulic press. The scanning range was 4000 to 400 cm-1. 
2.4. Stability studies 
The extrudates equivalent to 50 mg metoprolol succinate was filled in off white coloured hard 
gelatin capsules (size 00). The capsules placed in high density polyethylene (HDPE) bottles 
sealed with induction sealing of aluminium were stored at 40°C and 75% relative humidity 
for 3 months. The appearance, drug release profiles, buoyancy and drug content of stability 
samples were compared with the initial samples. 
 
3. Results and Discussion 
HME is a widely used technique for the development of several types of drug delivery 
systems. Extrudates obtained by HME generally exhibit enhanced density, a property not 
ideal for floating. Design of floating multiparticulates by HME is therefore challenging. 
Further as not all polymers are amenable for HME, formulation design is limited by the 
polymer selection afforded. Polymers extensively explored for HME include Eudragits, PEO 
and selected cellulose based polymers like HPMC, hydroxypropyl methylcellulose phthalate, 
and hydroxypropyl methylcellulose acetate succinate. Among these Eudragits and PEO 
which are low melting polymers are the most widely explored. In the present study Eudragit® 
RS PO a pH independent polymer was selected as it exhibits low Tg and low torque during 
extrusion (Wu and  McGinity, 2003, Dierickx et al., 2012) while PEO was employed due to 
its swelling and gelling property (Lei Li, et al., 2006) which proposed its application as a 
controlled release polymer. Glyceryl monostearate served as a lipophilic thermal lubricant 
(Zhu, et al., 2004). 
Incorporation of sodium bicarbonate in matrix tablets is a proven strategy for flotation of 
tablets in acidic media. Floating tablets of cephalexin are reported using HPMC as matrix and 
sodium bicarbonate as a gas forming agent (Yin et al., 2013). Tablets of valacyclovir 
hydrochloride containing PEO and sodium bicarbonate exhibited prolonged buoyancy due to 
entrapment of carbon dioxide (CO2) in the polymer gel matrix (Upadhyay et al., 2014). 
Matrix tablets of ciprofloxacin comprising HPMC and sodium alginate as gelling agent and 
sodium bicarbonate or calcium carbonate as effervescent agent enabled floating with 
controlled release up to 12 hours (Tadros, 2010). Bilayered tablets comprising HPMC as 
release modifier and sodium bicarbonate as effervescent agent exhibited immediate release of 
pioglitazone hydrochloride and prolonged floating with controlled release of metformin 
hydrochloride up to 12 hours (Wei et al., 2014). We extrapolated this concept of entrapping 
gas in polymer matrices to design floating multiparticulate drug delivery system by including 
sodium bicarbonate in the formulation (Table 1). 
A maximum screw speed of 15 rpm was considered optimum as at higher speeds the torque 
increased, probably due to the narrow die of 2mm used in the study. Further continuous 
increase in the temperature of the extruder zones facilitated ease of extrusion. Conventionally 
the temperature of the final zone and the die are maintained the same. In our study the die 
temperature was increased marginally to 128°C compared to 125°C maintained in zone 8 to 
enable smoother extrusion.  
Eudragit® RS PO alone exhibited low torque and ease of processing but no flotation was 
observed even after addition of sodium bicarbonate (FM1). Furthermore the resulting 
extrudates revealed a rough and porous surface implying that although CO2 was generated in 
situ the same had escaped. Replacing Eudragit® RS PO partially with PEO revealed a gradual 
increase in torque, nevertheless even at 60% (w/w) PEO the torque was significantly low and 
the mass was easily extrudable (Table 1).  
All extrudates were cut in to 5 mm length and had average diameter of 2 mm. Eudragit® RS 
PO and PEO with sodium bicarbonate (FM2) exhibited rapid flotation confirming the 
feasibility of this strategy. Although rapid FLT of 3 minutes was observed, the TFT of less 
than 1.5 hour was grossly inadequate. Increase in PEO concentration enabled decrease in 
FLT with a marginal enhancement in TFT to about 3 hours (Fig.1). However in-vitro release 
rate increased probably due to corresponding decrease in Eudragit® RS PO concentration 
(Fig.2).  A maximum t50% of 4.06 hours and t90% of 8.22 hours was achievable. 
Controlled release formulations dictate a TFT of at least 10 hours and the desirable t50% and 
t90% values for our study were >5 and >10 hours respectively. HPMC K100M a swelling 
gelling polymer is extensively reported for controlled release (Li et al., 2005) and could also 
enable flotation (Baumgartner et al., 2000, Yin et al., 2013). Inclusion of HPMC in the 
extrudates influenced both process and product parameters. Increase in HPMC concentration 
resulted in increase in torque (Table 1), with a very high torque seen at 20% (w/w) HPMC 
concentration (FM8), thereby limiting the HPMC concentration in the extrudates to 15%, 
w/w (FM7). Increase in the concentration of HPMC revealed an increase in both FLT and 
TFT (Fig.3). At HPMC 15%, w/w ( FM7) extrudates  revealed t50% of 5.24 hours and t90% of 
10.12 hours (Fig. 4), which was significantly greater than (P<0.05) the values seen without 
HPMC (FM5) with f2 value of 23.68 for in vitro release.  Although the f2 value for 
compositions with 10% (w/w) HPMC (FM6) and 15% (w/w) HPMC (FM7) was 62.64, the 
t50% for FM6 was significantly lower. Hence FM7 was modified further. 
Maintaining HPMC concentration at 15% (w/w), increase in sodium bicarbonate revealed 
decrease in FLT with no effect on TFT, while increase in Eudragit® RS PO concentration 
revealed increase in FLT (Fig.5). Nevertheless these changes revealed no significant effect on 
drug release (Fig.6) as confirmed by similarity factor (f2 >50). The formulations revealed 
diameter between 1.98 to 2.09 mm, length 4.92 to 5.11mm, density of 1.018 to 1.203 g/cm3, 
and drug content between 98.54 to 100.02%. The optimized formulation (FM7) exhibited 
FLT of 3 minutes with TFT greater than 12 hours and t50% and t90% values of 5.24 and 10.12 
hours respectively.  
To evaluate the kinetics and mechanism of drug release, the in-vitro dissolution data of FM7 
was subjected to different mathematical models, such as zero order, first order, Hixson–
Crowell model, Higuchi, and Korsmeyer-Peppas model. 
The result of the curve fitting into these mathematical models above is given in Table 2. It 
was found that the in-vitro dissolution data was well fitted to the zero order mathematical 
model (R2= 0.9955) which indicated that the optimized formulation exhibits zero order drug 
release kinetics wherein concentration independent and constant rate drug release is observed 
(Acharya et al., 2014). The value of diffusional exponent n in the Korsemeyer-Peppas model 
was found to be 0.74. This suggested the possibility of anomalous transport due to 
contribution of both swelling and diffusion. (Desai et al., 2014, Korsmeyer et al., 1983, Qi et 
al., 2015). Hence swelling coupled with effervescence induced porosity in the matrices could 
have enabled zero order release as seen (Table 2). 
3.1. X-ray diffraction analysis 
Crystalline nature of pure Metoprolol succinate is shown in the x-ray diffraction profile    
(Fig. 7). The XRD of metoprolol succinate showed sharp peaks at an angle of 14.42, 20.08 
and 23.62 (2θ). XRD pattern of FM7 exhibited corresponding peaks with decrease in 
intensity of the peaks indicating a decrease in the crystallinity of the drug. The peak at 30.44 
(2θ) of sodium bicarbonate was also observed in the XRD pattern of suggesting crystalline 
nature. 
 
3.2. Differential scanning calorimetry analysis 
The DSC thermogram of metoprolol succinate revealed a sharp endothermic peak at 136.4 °C 
which corresponds to the melting point of metoprolol succinate (Fig. 8). The thermogram of 
FM7 also exhibited the characteristic endotherm of metoprolol succinate, indicating 
crystalline state of the drug and no interaction with other excipients. In the thermogram of 
FM7 the endotherm observed at 69.9°C corresponds to melting of PEO, while the endotherm 
at 159.6°C is attributed to degradation of sodium bicarbonate. 
 
3.3. Fourier transform infrared analysis 
Infrared spectrum of metoprolol succinate revealed –NH symmetric stretching at 3147 cm–1 
due to secondary amine,  –C=O stretching at 1620 cm–1 due to succinic acid, –C=C– ring 
stretching at 1481 cm–1, and –C–O–C– asymmetric stretching at 1242 cm–1. Infrared 
spectrum of FM7 revealed all the characteristic peaks of metoprolol succinate, –NH 
stretching of secondary amine at 3153 cm–1, –C=O stretching of succinic acid at 1620 cm–1, 
and –C=C– ring stretching of metoprolol succinate at 1473 cm–1 and –C–O–C– asymmetric 
stretching at 1242 cm–1 which clearly shows the nonexistence of any chemical interaction 
between the drug and the other excipients even at elevated operating temperatures during 
HME process (Fig. 9). 
 
3.4. Stability studies 
Formulation FM7 was evaluated for stability.  In-vitro buoyancy study of extrudates revealed 
FLT and TFT comparable to the zero time samples. No significant difference in drug release 
profile was observed during three months stability as indicated by t50% and t90% values and f2 
values >50 as well as f1 value <15 (Table 3) confirming stability of the floating 
multiparticulates of metoprolol succinate. 
 
4. Conclusion 
We present HME for design of floating multiparticulate drug delivery systems. The 
successful design of floating controlled release multiparticulates of a water soluble drug 
metoprolol succinate proposes this approach as platform technology which could be 
extrapolated to a range of other drugs with varying solubility. 
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Table 1: Composition of hot melt extruded multiparticulate formulations (%, w/w) and 
resulting torque 
 
Formulation 
Code 
Metoprolol 
Succinate 
Sodium 
Bicarbonate 
HPMC Eudragit® 
RS PO 
Glyceryl Mono 
Stearate 
PEO Torque 
(Nm) 
FM1 10 10 - 75 5 - 30-32 
FM2 10 10 - 45 5 30 33-35 
FM3 10 10 - 30 5 45 36-39 
FM4 10 10 - 15 5 60 44-47 
FM5 10 5 - 15 5 65 42-46 
FM6 10 5 10 15 5 55 56-59 
FM7 10 5 15 15 5 50 65-71 
FM8 10 5 20 15 5 45 >90 
FM9 10 5 15 10 5 55 82-86 
FM10 10 5 15 20 5 45 53-58 
FM11 10 5 15 25 5 40 48-51 
FM12 10 10 15 15 5 45 67-70 
FM13 10 15 15 15 5 40 69-73 
 
 
 
Table 2: Results of mathematical models after curve fitting of in-vitro drug release data of 
FM7 
 
Models Slope Intercept R-square 
Zero order 8.2004 7.0069 0.9955 
First order 0.1863 2.2814 0.8126 
Hixon-Crowell 3.2807 0.9282 0.9493 
Higuchi 29.4812 10.4340 0.9816 
Korsmeyer-Peppas 1.1858 2.4361 0.8301 
 
 
 
Table 3: Stability data for floating multiparticulates of metoprolol succinate (FM7) 
 
Parameters Initial One month Two months Three 
months 
Floating lag time (sec) 176 ± 3.60 174 ± 1.53 171 ± 2.08 167 ± 1.53 
Total floating time (h) >12 >12 >12 >12 
Assay (%) 99.85 ± 0.11 99.71 ± 0.20 99.04 ± 0.16 99.53 ± 0.25 
t50 (h) 5.24 5.07 4.9 4.76 
t90 (h) 10.12 9.92 9.72 9.57 
f2 value reference 84.69 72.84 64.69 
f1 value reference 3.36 6.6 9.25 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Effect of concentration of PEO on floating lag time and total floating time of floating multiparticulates 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Effect of concentration of PEO on in-vitro release of metoprolol succinate 
 
 
 
 
 
 
 
 
 
 
 
 Fig.3. Effect of concentration of HPMC on floating lag time and total floating time of floating multiparticulates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.4. Effect of concentration of HPMC on in-vitro release of metoprolol succinate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.5. Effect of concentration of sodium bicarbonate and Eudragit® RS PO on floating lag time of floating 
multiparticulates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig.6. Effect of concentration of Eudragit® RS PO (a) and sodium bicarbonate (b) on in-vitro release of metoprolol 
succinate 
 
 
 
 
 
 
 
 
 
 
 Fig.7. Powder X-ray diffraction patterns of sodium bicarbonate, glyceryl monostearate, metoprolol succinate, PEO, HPMC, 
Eudragit® RS PO, and FM7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.8. DSC thermograms of FM7, HPMC, Eudragit® RS PO, sodium bicarbonate, PEO, metoprolol succinate and glyceryl 
monostearate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig.9. FTIR spectrum of metoprolol succcinate (a) and FM7 (b) 
 
 
 
 
 
